Table 3.
Interventional studies from Egypt in 3 clinical trial registries.
| CTGR | ICTRP | PACTR | |
|---|---|---|---|
| n (%) | n (%) | n (%) | |
| Total | 458 | 580 | 56 |
| Intervention | |||
| Drug | 316 (69.0) | –a | 30 (53.6) |
| Procedure | 64 (14.0) | –a | 11 (19.6) |
| Biological | 22 (4.7) | –a | 0 (0) |
| Device | 16 (3.5) | –a | 0 (0) |
| Radiation | 11 (2.4) | –a | 5 (8.9) |
| Dietary supplement | 6 (1.3) | –a | 2 (3.6) |
| Behavioral | 3 (0.7) | –a | 0 (0) |
| Other | 20 (4.4) | –a | 8 (14.3) |
| Study phase | |||
| Phase 3 | 151 (33.0) | 119 (20.5) | 48 (85.7) |
| Phase 4 | 77 (16.8) | 83 (14.3) | 0 (0) |
| Phase 2 | 67 (14.6) | 67 (11.6) | 3 (5.4) |
| Phase 2|Phase 3 | 27 (5.9) | 26 (4.5) | 5 (8.9) |
| Phase 1|Phase 2 | 16 (3.49) | 21 (3.6) | 0 (0) |
| Phase 1 | 12 (2.6) | 13 (2.2) | 0 (0) |
| Phase 0 | 7 (1.5) | 6 (1.0) | 0 (0) |
| Phase 3/phase 4 | 0 (0) | 4 (0.7) | 0 (0) |
| Unknown | 101 (22.05) | 241 (41.6) | 0 (0) |
| Model | |||
| Parallel assignment | 320 (69.9) | 326 (56.2) | 50 (89.3) |
| Single group assignment | 106 (23.1) | 103 (22.4) | 3 (5.4) |
| Crossover assignment | 5 (1.1) | 2 (0.4) | 2 (3.6) |
| Factorial assignment | 4 (0.9) | 4 (0.7) | 1 (1.8) |
| Not mentioned | 113 (24.7) | 145 (25.0) | 0 (0) |
| Allocation | |||
| Randomized | 355 (77.5) | 380 (65.5) | 48 (85.7) |
| Non-randomized | 50 (10.9) | 66 (11.4) | 5 (8.9) |
| NM/Other | 53 (11.6) | 134 (23.1) | 3 (5.4) |
| Masking | |||
| Open label | 226 (49.3) | 220 (37.9) | 13 (23.2) |
| Double blind | 168 (36.7) | 182 (31.4) | 24 (42.9) |
| Single blind | 50 (10.9) | 77 (13.3) | 19 (33.9) |
| Unknown | 114 (24.9) | 101 (17.4) | 0 (0) |
CTGR: U.S. ClinicalTrials.gov registry, ICTRP: WHO International Clinical Trials Registry Platform, PACTR: Pan-African Clinical Trials Registry.
a
Not included.